The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Seminars in hematology (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.seminhematol.2013.11.001PMID 24468313
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.

  2014cited by this paper
• Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

  2014cited by this paper
• Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology

  2013cited by this paper
• Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

  2013cited by this paper
• Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.

  2013cited by this paper
• Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.

  2013cited by this paper
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

  2013cited by this paper
• Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

  2013cited by this paper
• A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

  2013cited by this paper
• Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

  2013cited by this paper
• The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives.

  2013cited by this paper
• Peripheral T-Cell Lymphomas: A Review of Current Approaches and Hopes for the Future

  2013cited by this paper
• Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.

  2013cited by this paper
• Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

  2013cited by this paper
• Pralatrexate Pharmacology and Clinical Development

  2013cited by this paper
• Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma

  2013cited by this paper
• Treatment strategies for peripheral T-cell lymphomas.

  2013cited by this paper
• The aggressive peripheral T‐cell lymphomas: 2013

  2013cited by this paper
• Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

  2012cited by this paper
• Mogamulizumab

  2012cited by this paper
• A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study

  2012cited by this paper
• How I treat enteropathy-associated T-cell lymphoma.

  2012cited by this paper
• Overview of alemtuzumab therapy for the treatment of T-cell lymphomas

  2012cited by this paper
• Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211.

  2012cited by this paper
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

  2012cited by this paper
• Current and future management of NK/T-cell lymphoma based on clinical trials

  2012cited by this paper
• Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.

  2012cited by this paper
• SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

  2012cited by this paper
• Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

  2012cited by this paper
• Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

  2012cited by this paper
• Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

  2011cited by this paper
• Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

  2011cited by this paper
• Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

  2011cited by this paper
• Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

  2011cited by this paper
• Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

  2011cited by this paper
• Enteropathy-associated T-cell lymphoma.

  2011cited by this paper
• Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

  2011cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

  2010cited by this paper
• Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

  2010cited by this paper
• Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

  2010cited by this paper
• Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.

  2010cited by this paper
• Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

  2010cited by this paper
• Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

  2010cited by this paper
• Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies

  2010cited by this paper
• Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma

  2010cited by this paper
• Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

  2009cited by this paper
• Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.

  2009cited by this paper
• Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia

  2008cited by this paper
• ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

  2008cited by this paper
• Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.

  2008cited by this paper
• Extranodal NK/T‐cell lymphoma: diagnosis and treatment cues

  2008cited by this paper
• Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

  2008cited by this paper
• International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

  2008cited by this paper
• CMED in the treatment of nasal natural killer cell lymphoma with distant metastases

  2007cited by this paper
• Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.

  2007cited by this paper
• Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

  2007cited by this paper
• Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

  2007cited by this paper
• Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group

  2007cited by this paper
• Expression of CD52 in peripheral T-cell lymphoma.

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

  2007cited by this paper
• Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma.

  2006cited by this paper
• Midline NK/T‐cell lymphoma nasal‐type: treatment outcome, the effect of L‐asparaginase based regimen, and prognostic factors

  2006cited by this paper
• The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

  2006cited by this paper
• Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

  2006cited by this paper
• The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

  2006cited by this paper
• The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas

  2005cited by this paper
• Monoclonal antibodies in the treatment of indolent lymphomas.

  2005cited by this paper
• Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma

  2005cited by this paper
• A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

  2004cited by this paper
• T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

  2004cited by this paper
• All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

  2004cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

  2003cited by this paper
• Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression

  2003cited by this paper
• Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

  2002cited by this paper
• Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

  2000cited by this paper
• CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial.

  1999cited by this paper

• synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy

  2026cites this paper
• Targeting cathepsin L in the regulation of apoptosis in peripheral T-cell lymphoma

  2023cites this paper
• Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma

  2021cites this paper
• Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma

  2020cites this paper
• Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

  2020cites this paper
• Novel Immunotherapies for T Cell Lymphoma and Leukemia

  2018cites this paper
• Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

  2018cites this paper
• Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab.

  2017cites this paper
• A Review of Autologous Stem Cell Transplantation in Lymphoma

  2017cites this paper
• Treatment approaches of hard-to-treat non-Hodgkin lymphomas

  2017influential citation
• Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

  2017cites this paper
• Treatment of Peripheral T‐Cell Lymphoma in Community Settings

  2017cites this paper
• Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis

  2017cites this paper
• Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

  2016influential citation
• Therapeutic options in peripheral T cell lymphoma

  2016cites this paper
• Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review

  2016cites this paper
• Histone Deacetylase Inhibitors Interrupt HSP90•RASGRP1 and HSP90•CRAF Interactions to Upregulate BIM and Circumvent Drug Resistance in Lymphoma Cells

  2016cites this paper
• Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data

  2016cites this paper
• Treatment of T cell lymphoma in dogs

  2016cites this paper
• Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

  2015cites this paper
• Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

  2015cites this paper
• Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins’ Lymphoma in First Remission

  2015cites this paper
• Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission

  2015cites this paper
• Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

  2015cites this paper
• Pathology of T-cell lymphomas: diagnosis and biomarker discovery.

  2015cites this paper
• T-CELL AND OTHER LYMPHOPROLIFERATIVE MALIGNANCIES ( P PORCU , SECTION EDITOR ) Targets , Toxins , and T Cells — a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

  2015cites this paper
• Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.

  2014cites this paper
• Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

  2014cites this paper
• A poor prognostic case of peripheral T-cell lymphoma in the base of tongue with chemotherapy followed by radiation therapy

  2014cites this paper